Speakers - Sachs Associates

CONTACT
Curt Bilby, PhD
President and CEO
ADDRESS
7000 North MoPac Expressway
2nd Floor
Austin, TX 78731
TELEPHONE
512 514 6760
FAX
512 287 4241
EMAIL
cbilby@terapio.com
YEAR FOUNDED
2006
Terapio Corporation
www.terapio.com
FINANCIAL SUMMARY
$6.7M Series A
$1M seed capital
$3.6M in federal funds
Terapio is seeking a lead or syndicate investors to participate with Santé Ventures in Terapio’s Series B financing.
Terapio plans at least $10M in Series B financing where Santé Ventures, the Series A lead investor, will
participate on a pro rata basis. The use of proceeds for Series B will be primarily used for drug development,
preclinical and nonclinical programs, and regulatory activities required to fund the company to the valuation
inflection point associated with completing the pivotal nonhuman primate efficacy trial under the FDA Animal
Rule.
COMPANY PROFILE
Launched in 2007 and backed by Santé Ventures, Terapio is a biopharmaceutical company developing clinical
applications based on the naturally-occurring RLIP76 protein. RLIP76 is a membrane-associated cellular
transport protein that is an integral part of the cell’s normal process of removing toxic metabolites formed by
oxidative insults. However, in cases of elevated oxidative stress, such as occurs with exposure to radiation and
chemical toxins, the endogenous RLIP76 system can be overwhelmed, leading to cell death. Supplementing
cellular levels of RLIP76 through exogenous administration of Terapio’s liposomal formulation of the RLIP76
protein promotes protection by relieving this cellular stress and allows recovery by tissue cells. This mechanism
of action has broad applicability to a variety of additional clinical indications, including the treatment of the toxic
side effects of therapeutic radiation and chemotherapy in oncology patients and CNS diseases – a key part of
Terapio’s commercial pipeline.
For biodefense applications, Terapio has accumulated a large body of data demonstrating that the protein is
effective in protecting and rescuing animals exposed to otherwise lethal exposures of whole body radiation.
Therefore, the company is pursuing the prevention and treatment of Acute Radiation Syndrome (ARS) as a lead
indication. No effective countermeasures for ARS exist today, making this a highly unmet need.
Terapio has performed multiple 30-day survival studies with the RLIP76 protein in animal models of ARS and
demonstrated that administered either before and/or after exposure to lethal doses of radiation results in greater
than 90% survival of treated animals, versus 20% survival of controls.
MANAGEMENT
Curt Bilby, PhD, President and CEO
Casey Cunningham, MD, co-founder and Chief Medical Officer
Henry Hebel, Vice President of Drug Development
Elizabeth Leffel, PhD, MPH, Vice President of Preclinical and Nonclinical Programs
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS